Crossject - Appointment of Daniel Teper to the Crossject Supervisory Board / Building skills to support the US transition
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Crossject - Appointment of Daniel Teper to the Crossject Supervisory Board / Building skills to support the US transition
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
Intec Pharma Ltd - Consensus Indicates Potential 120 0% Upside
directorstalkinterviews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from directorstalkinterviews.com Daily Mail and Mail on Sunday newspapers.
Intec Closes Merger with Decoy Biosystems
USA - English
Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus
News provided by
Share this article
Share this article
NEW YORK, Aug. 3, 2021 /PRNewswire/ Indaptus Therapeutics, Inc. (Nasdaq: INDP) ( Indaptus or the Company, and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ( Decoy ) and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company s therapeutic focus.
Indaptus is expected to begin trading on the Nasdaq Capital Market at the open of trading on August 4, 2021, under the ticker symbol INDP and a new CUSIP number (45339J 105). The previous ticker symbol was NTEC (Nasdaq: NTEC). The Company will have a new website address: www.indaptusrx.com.